Last Updated: June 25, 2026

Patent: 10,047,116


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,047,116
Title:Nanoparticles, process for preparation and use thereof as carrier for amphipatic and hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
Abstract: The present invention regards nanoparticles comprising a sterol and a component derived from Quillaja saponaria Molina selected from quillaja acid and quillaja saponin, which nanoparticles do not comprise a phospholipid. It also relates to a composition comprising the nanoparticles, and the use thereof as adjuvant, especially in vaccines, as carriers for amphipathic or hydrophobic molecules and as agents for treatment of cancer. Further, it regards a method for producing the phospholipid-free nanoparticles, a method for the treatment of cancer and a method for assessing the applicability of the cancer treating method.
Inventor(s): Morein; Bror (Uppsala, SE), Berenjian; Saideh (Uppsala, SE), Hu; Kafei (Uppsala, SE)
Assignee: MX Adjuvac AB (Enkoping, SE)
Application Number:14/349,142
Patent Claims:see list of patent claims

Details for Patent 10,047,116

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Seqirus Vaccines Limited FLUVIRIN influenza virus vaccine Injection 103837 November 03, 1998 ⤷  Start Trial 2032-10-01
Sanofi Pasteur Inc. FLUZONE, FLUZONE HD QUADRIVALENT, FLUZONE HIGH DOSE, FLUZONE INTRADERMAL, FLUZONE QUADRIVALENT influenza virus vaccine Injection 103914 December 09, 1999 ⤷  Start Trial 2032-10-01
Sanofi Pasteur Inc. FLUZONE, FLUZONE HD QUADRIVALENT, FLUZONE HIGH DOSE, FLUZONE INTRADERMAL, FLUZONE QUADRIVALENT influenza virus vaccine Injection 103914 December 23, 2009 ⤷  Start Trial 2032-10-01
Sanofi Pasteur Inc. FLUZONE, FLUZONE HD QUADRIVALENT, FLUZONE HIGH DOSE, FLUZONE INTRADERMAL, FLUZONE QUADRIVALENT influenza virus vaccine Injection 103914 May 09, 2011 ⤷  Start Trial 2032-10-01
Sanofi Pasteur Inc. FLUZONE, FLUZONE HD QUADRIVALENT, FLUZONE HIGH DOSE, FLUZONE INTRADERMAL, FLUZONE QUADRIVALENT influenza virus vaccine Injection 103914 June 07, 2013 ⤷  Start Trial 2032-10-01
Sanofi Pasteur Inc. FLUZONE, FLUZONE HD QUADRIVALENT, FLUZONE HIGH DOSE, FLUZONE INTRADERMAL, FLUZONE QUADRIVALENT influenza virus vaccine Injection 103914 December 11, 2014 ⤷  Start Trial 2032-10-01
Sanofi Pasteur Inc. FLUZONE, FLUZONE HD QUADRIVALENT, FLUZONE HIGH DOSE, FLUZONE INTRADERMAL, FLUZONE QUADRIVALENT influenza virus vaccine Injection 103914 November 04, 2019 ⤷  Start Trial 2032-10-01
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.